Hélène Caillon

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 922 citations · Full text

Hematological Malignancy, Radiation Oncology, Medicine +9

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau, Cyrille Hulin, Margaret Macro et al. · Blood · 2016 · 273 citations · Full text

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2021 · 167 citations · Full text

Hematological Malignancy, Medicine, Autologous Stem-cell Transplant +6

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2024 · 94 citations · Full text

Hematological Malignancy, Medicine, Daratumumab Maintenance +8

Evaluation of sFlt-1/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care Center

Hélène Caillon, Cécile Tardif, Erwan Dumontet et al. · Annals of Laboratory Medicine · 2017 · 74 citations · Full text